Efficacy and Tolerability of SkinPen on Male and Female Subjects' Wrinkles of the Neck
NCT ID: NCT03803059
Last Updated: 2021-12-01
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
35 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-01-31
Study Completion Date
2020-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This single-center, the clinical trial is being conducted over the course of 90 days followed by 1-month and 6-month post-treatment visits in order to assess the efficacy and tolerability of the Sponsor's SkinPen device when used by men and women with the wrinkles of the neck.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 32 subjects completed study participation.
At visit 1 (baseline), subjects were screened for eligibility criteria, and those who qualified either completed day 1 procedures at the same visit or returned to the clinic up to 14 days after visit 1 to complete day 1 procedures at visit 2.
On days 1, 30, 60, and 90, after completion of visit assessments, doctors or fellows at the testing facility (henceforth referred to as "clinic") treated each subject's wrinkles of the neck with SkinPen Precision System at depths of up to 2.5mm.
During the post-treatment period, Clinical evaluations were conducted at visit 2 (day 1), visit 3 (day 30), visit 4 (day 60), visit 5 (day 90), visit 6 (1month post-treatment), and visit 7 (3 months post-treatment)
At visit 1 (baseline), subjects were screened for eligibility criteria, and those who qualified either completed day 1 procedures at the same visit or returned to the clinic up to 14 days after visit 1 to complete day 1 procedures at visit 2.
On days 1, 30, 60, and 90, after completion of visit assessments, doctors or fellows at the testing facility (henceforth referred to as "clinic") treated each subject's wrinkles of the neck with SkinPen Precision System at depths of up to 2.5mm.
During the post-treatment period, Clinical evaluations were conducted at visit 2 (day 1), visit 3 (day 30), visit 4 (day 60), visit 5 (day 90), visit 6 (1month post-treatment), and visit 7 (3 months post-treatment)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Wrinkles
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wrinkles of the Neck
Microneedle treatment neck areas.
Group Type
EXPERIMENTAL
SkinPen Precision
Intervention Type
DEVICE
Surgical instrument motors and accessories/attachments/Hydrogel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SkinPen Precision
Surgical instrument motors and accessories/attachments/Hydrogel
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
At least 20% of subjects will have Fitzpatrick skin types IV-VI Individuals who grade a 4 or higher on the Fitzpatrick Wrinkle Scale Individuals that desire correction of their wrinkles Individuals willing to withhold aesthetic therapies to the areas of the neck being treated or judged to potentially impact results by the Investigator.
Women of childbearing potential agree to take a urine pregnancy test at the Baseline visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This may be changed to one monthly pregnancy test at the Sponsor's discretion. Women who are of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the baseline visit. Women must be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
* Postmenopausal for at least 12 months prior to the study;
* Without a uterus and/or both ovaries;
* Bilateral tubal ligation at least 6 months prior to study enrollment. Women of child bearing potential agree to take a urine pregnancy test at the Baseline visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This may be changed to one month pregnancy test at the Sponsor's discretion. Women who are of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the baseline visit. Women must be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
* Postmenopausal for at least 12 months prior to the study;
* Without a uterus and/or both ovaries;
* Bilateral tubal ligation at least 6 months prior to study enrollment.
Individuals of child-bearing potential who use an acceptable method of contraception throughout the study. Acceptable methods of birth control include:
1. Established use of hormonal methods of contraception (oral, injected, implanted, patch, or vaginal ring).
2. Barrier methods of contraception with spermicide: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
3. Intrauterine device (IUD) or intrauterine system (IUS)
4. Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal occlusion, hysterectomy, bilateral salpingectomy/oophorectomy)
5. Abstinence from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
* Individuals that are willing to provide written informed consent and are able to read, speak, write, and understand English.
* Individuals willing to sign a photography release.
* Willingness to cooperate and participate by following study requirements (including those outlined in section 5.5) for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately.
Women of childbearing potential agree to take a urine pregnancy test at the Baseline visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This may be changed to one monthly pregnancy test at the Sponsor's discretion. Women who are of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the baseline visit. Women must be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
* Postmenopausal for at least 12 months prior to the study;
* Without a uterus and/or both ovaries;
* Bilateral tubal ligation at least 6 months prior to study enrollment. Women of child bearing potential agree to take a urine pregnancy test at the Baseline visit and 6-months post-treatment or when deemed by Investigator and/or Sponsor. This may be changed to one month pregnancy test at the Sponsor's discretion. Women who are of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the baseline visit. Women must be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
* Postmenopausal for at least 12 months prior to the study;
* Without a uterus and/or both ovaries;
* Bilateral tubal ligation at least 6 months prior to study enrollment.
Individuals of child-bearing potential who use an acceptable method of contraception throughout the study. Acceptable methods of birth control include:
1. Established use of hormonal methods of contraception (oral, injected, implanted, patch, or vaginal ring).
2. Barrier methods of contraception with spermicide: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
3. Intrauterine device (IUD) or intrauterine system (IUS)
4. Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal occlusion, hysterectomy, bilateral salpingectomy/oophorectomy)
5. Abstinence from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
* Individuals that are willing to provide written informed consent and are able to read, speak, write, and understand English.
* Individuals willing to sign a photography release.
* Willingness to cooperate and participate by following study requirements (including those outlined in section 5.5) for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately.
Exclusion Criteria
* Individuals diagnosed with known allergies to facial or general skincare products.
* Individuals who have the presence of an active systemic or local skin disease that may affect wound healing.
* Individuals who have severe solar elastosis.
* Individuals with sensitivity to topical lidocaine.
* Individuals who have physical or psychological conditions unacceptable to the Investigator.
* Individuals who have a recent history of significant trauma to the areas to be treated (\< 6 months).
* Individuals who have significant scarring, other than acne scars, in the area(s) to be treated.
* Individuals who have severe or cystic active and clinically significant acne on the area(s) to be treated. Clinically significant acne is defined as a subject who has \> 5 active inflammatory acne lesions (including acne conglobate, nodules, or cysts) in either the right or left treatment area.
* Individuals who have a recent or current history of inflammatory skin disease, infection, cancerous/pre-cancerous lesion, unhealed wound or clinically significant acne in the proposed treatment areas. Individuals who have a history of systemic granulomatous diseases, active or inactive, (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus, dermatomyositis, etc.).
* Individuals who currently have or have a history of hypertrophic scars or keloid scars.
* Individuals who currently have cancerous or pre-cancerous lesions in the areas to be treated and/or with a history of skin cancer.
* Individuals who have the inability to understand instructions or to give informed consent.
* Individuals who have had microdermabrasion or glycolic acid treatment to the treatment area(s) within 1 month prior to study participation or who will have this treatment during the study.
* Individuals who have a history of chronic drug or alcohol abuse.
* Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
* Individuals who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
* Individuals who are current smokers or have smoked in the last 5 years.
* Individuals who have a history of the following cosmetic treatments in the area(s) to be treated:
* Skin tightening procedure within the past year;
* Injectable filler of any type within the past:
* 12 months for Hyaluronic acid fillers (e.g. Restylane)
* 12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)
* 24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)
* Ever for permanent fillers (e.g. Silicone, ArteFill)
* Neurotoxins within the past 3 months;
* Ablative resurfacing laser treatment;
* Non-ablative, rejuvenating laser or light treatment within the past 6 months;
* Surgical dermabrasion or deep facial peels;
* Had a chemical peel, dermabrasion, non-ablative laser, or fractional laser resurfacing of the neck within 4 weeks
* Individuals with a history of using the following prescription medications:
* Accutane or other systemic retinoids within the past 6 months;
* Topical Retinoids within the past 2 weeks;
* Prescription-strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA, BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with tretinoin, etc.) within 4 months;
* Any anti-wrinkle, skin lightening devices, or any other device or topical or systemic medication is known to affect skin aging or dyschromia (devices containing alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250, Giga white, lemon juice extract (topically), Emblica extract, etc.) within 2 weeks;
* Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID use); and/or
* Psychiatric drugs that in the Investigator's opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.
* Individuals who are nursing, pregnant, or planning to become pregnant during the study according to the subject self-report.
* Individuals having a health condition and/or pre-existing or dormant dermatologic disease on the face or body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post-inflammatory hyperpigmentation) that the Investigator or designee deems inappropriate for participation or could interfere with the outcome of the study.
* Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
* Individuals with uncontrolled diseases such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
* Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study.
* Individuals who are currently participating in any other study involving the use of investigational devices or drugs or have participated in any clinical trial at UT Southwestern or at another research facility or doctor's office within 4 weeks prior to inclusion into the study.
* Individuals who have an observable suntan, nevi, excessive hair, etc. or other dermal conditions on the neck that might influence the test results in the opinion of the Investigator or designee.
* Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments).
* Individuals who started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of HRT or hormones for birth control during the study.
* Individuals who have the presence of an active systemic or local skin disease that may affect wound healing.
* Individuals who have severe solar elastosis.
* Individuals with sensitivity to topical lidocaine.
* Individuals who have physical or psychological conditions unacceptable to the Investigator.
* Individuals who have a recent history of significant trauma to the areas to be treated (\< 6 months).
* Individuals who have significant scarring, other than acne scars, in the area(s) to be treated.
* Individuals who have severe or cystic active and clinically significant acne on the area(s) to be treated. Clinically significant acne is defined as a subject who has \> 5 active inflammatory acne lesions (including acne conglobate, nodules, or cysts) in either the right or left treatment area.
* Individuals who have a recent or current history of inflammatory skin disease, infection, cancerous/pre-cancerous lesion, unhealed wound or clinically significant acne in the proposed treatment areas. Individuals who have a history of systemic granulomatous diseases, active or inactive, (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus, dermatomyositis, etc.).
* Individuals who currently have or have a history of hypertrophic scars or keloid scars.
* Individuals who currently have cancerous or pre-cancerous lesions in the areas to be treated and/or with a history of skin cancer.
* Individuals who have the inability to understand instructions or to give informed consent.
* Individuals who have had microdermabrasion or glycolic acid treatment to the treatment area(s) within 1 month prior to study participation or who will have this treatment during the study.
* Individuals who have a history of chronic drug or alcohol abuse.
* Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
* Individuals who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
* Individuals who are current smokers or have smoked in the last 5 years.
* Individuals who have a history of the following cosmetic treatments in the area(s) to be treated:
* Skin tightening procedure within the past year;
* Injectable filler of any type within the past:
* 12 months for Hyaluronic acid fillers (e.g. Restylane)
* 12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)
* 24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)
* Ever for permanent fillers (e.g. Silicone, ArteFill)
* Neurotoxins within the past 3 months;
* Ablative resurfacing laser treatment;
* Non-ablative, rejuvenating laser or light treatment within the past 6 months;
* Surgical dermabrasion or deep facial peels;
* Had a chemical peel, dermabrasion, non-ablative laser, or fractional laser resurfacing of the neck within 4 weeks
* Individuals with a history of using the following prescription medications:
* Accutane or other systemic retinoids within the past 6 months;
* Topical Retinoids within the past 2 weeks;
* Prescription-strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA, BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with tretinoin, etc.) within 4 months;
* Any anti-wrinkle, skin lightening devices, or any other device or topical or systemic medication is known to affect skin aging or dyschromia (devices containing alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250, Giga white, lemon juice extract (topically), Emblica extract, etc.) within 2 weeks;
* Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID use); and/or
* Psychiatric drugs that in the Investigator's opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.
* Individuals who are nursing, pregnant, or planning to become pregnant during the study according to the subject self-report.
* Individuals having a health condition and/or pre-existing or dormant dermatologic disease on the face or body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post-inflammatory hyperpigmentation) that the Investigator or designee deems inappropriate for participation or could interfere with the outcome of the study.
* Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
* Individuals with uncontrolled diseases such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
* Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study.
* Individuals who are currently participating in any other study involving the use of investigational devices or drugs or have participated in any clinical trial at UT Southwestern or at another research facility or doctor's office within 4 weeks prior to inclusion into the study.
* Individuals who have an observable suntan, nevi, excessive hair, etc. or other dermal conditions on the neck that might influence the test results in the opinion of the Investigator or designee.
* Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments).
* Individuals who started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of HRT or hormones for birth control during the study.
Minimum Eligible Age
35 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bellus Medical, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey Kenkel, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas Southwestern Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Texas Southwestern Medical Center
Dallas, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Alqam M, Wamsley CE, Hitchcock TM, Jones BC, Akgul Y, Kenkel JM. Efficacy and tolerability of a microneedling device for treating wrinkles on the face. J Cosmet Dermatol. 2023 Jan;22(1):206-213. doi: 10.1111/jocd.14985. Epub 2022 Jun 2.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bellmed002
Identifier Type: -
Identifier Source: org_study_id